The Difference is in the Data®

Strong science, strength of process, and a sense of urgency, MMS is redefining the CRO experience.

Learn more about the MMS difference

Regulatory Affairs
& Operations

Data Management
& Biostatistics

Regulatory
& Medical Writing

Drug Safety
& Pharmacovigilance

Compliance
& Transparency

Data
Sciences

Helping sponsors navigate a complex regulatory environment

MMS is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards.

Industry experts across 4 continents are available to support your programs 24×7 with a 97 percent sponsor satisfaction rating

“MMS is the only company I would reach out to, big or small. MMS understood and worked within our capabilities and with our unconventional strategies we were forced into by the nature of being small and underfunded. Your team worked with us, diligently, beyond expectations, and got us over the finish line to success.”

—Sr. Vice President, Research & Development, Small Pharma

“This team never stopped working towards our deadline, and from day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.”

—Randy Brenner, Senior Vice President Global Regulatory Affairs, Quality, and Technical Operations, Paratek

“We work with a lot of CROs and consultants here in Boston. They’re good, they do fine, but you guys are the standard.”

— Senior Director, Clinical Quality Assurance, Large Pharma

“MMS consistently provides our team with the highest level of detail and quality work in every task that they undertake. I am pleased that we were able to attain this fast track status and look forward to working with MMS as we continue into the phase three studies.”

— Dr. Doo Lee, CEO and Head of Research and Development, Vivozon

“The choice in collaborating with MMS to meet this milestone… was simple, given their deep scientific knowledge and strategic resource models,”

— Dr. Steven Gullans, CEO, Gemphire

From the MMS Blog

How Real World Data is Changing the Pharmaceutical Industry

Approximately 90 percent of global pharmaceutical companies are using, or have plans to use real world data in the near future, according to a 2018 benchmarking survey from Deloitte. Ten to twenty years from now, using real world evidence in clinical trials will be second nature, but we – as an industry – must do the work to get to that point. Read the article

Featured Sponsor

Submission Support for Paratek Pharmaceuticals Garners FDA Approval and Successful MAA Filing

MMS supported Paratek Pharmaceuticals, Inc. for the new drug application (NDA) approval and successful marketing authorisation application (MAA) filing of NUZYRA™ (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Get the details

Latest News

MMS ANNOUNCES USD1M AWARD FOR COVID-19 VACCINE DEVELOPMENT

MMS funds Zika vaccine coronavirus covid-19 USD1m development award vaccine mms holdings CRO canton Michigan contract research organization clinical research organization corona virus MMS announced that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus. “Our goal is to help eliminate financial roadblocks associated with pursuing approval of a treatment in this area. This team’s experience with clinical data, especially in the area of vaccines, puts MMS in a strong position to support this vital community need,” said Dr. Uma Sharma, Chief Scientific Officer, MMS. Read more

Strategic Partnership

MMS partners with MIT Julia Lab and University of Maryland to create the Health Analytics Collective

The timeline to market a new drug or medical device, from the point of discovery to U.S. Food and Drug Administration approval, can stretch to a decade. By pooling its industry experience and technology, a new health research supergroup led by the Julia Lab within the MIT Computer Science and Artificial Intelligence Laboratory aims to significantly shorten the approval process for pharmaceutical and health care groups. Learn more